AstraZeneca stock dives 9% after heart drug trial misses target

CNBC Published Updated Stocks
Sign in to save

Expected market reaction

Neutral Confidence 50% How confidence is read Horizon: Short term Impact: Low

Evidence trail

Evidence
Source CNBC
Claim AstraZeneca stock dives 9% after heart drug trial misses target
AI inference Neutral · 50%
Generated 2026-07-09 07:59

AI provenance

Analysed by Rule-Based Analysis not AI Methodology v1.0 Generated
Technical identifiers
Provider tag
free-analysis-rule-based-analysis
Analysis version
free-analysis-rule-based-analysis
Article id
105401

Original source

A late-stage clinical trial failed to miss its primary endpoint, U.K.'s laregst drugmaker said Thursday.

Read the full article on CNBC

Original article published by CNBC on July 9, 2026. Analysis and insights provided by AnalystMarkets AI.

Related coverage

This model on similar stories

Rule-Based Analysis · 34.2% correct across 732 scored calls on equities See the full record